Table 3. Self-reported History of High-Risk Allergy and Risk of an Allergic Reaction Within 3 Days After mRNA COVID-19 Vaccination.
| Allergic reaction | High-risk allergy history, No. (%) | Adjusted relative risk (95% CI)a | P value for interaction | |
|---|---|---|---|---|
| With | Without | |||
| Either dose 1 or dose 2 by sex | ||||
| Male | 7 (7.7) | 505 (3.4) | 2.50 (1.27-5.32) | .85 |
| Female | 48 (12.5) | 1956 (5.2) | 2.40 (1.91-3.26) | |
| Either dose 1 or dose 2 by age, y | ||||
| ≥55 | 14 (9.2) | 478 (4.1) | 2.24 (1.35-3.72) | .60 |
| <55 | 41 (12.8) | 1983 (4.9) | 2.63 (1.97-3.51) | |
| Either dose 1 or dose 2 by race | ||||
| Black | 6 (13.3) | 190 (7.5) | 1.94 (0.91-4.13) | .62 |
| White | 34 (10.6) | 1495 (4.3) | 2.59 (1.88-3.57) | |
| Otherb | 15 (13.9) | 776 (5.2) | 2.59 (1.62-4.14) | |
| Either dose 1 or dose 2 by vaccine manufacturer | ||||
| Moderna | 33 (15.3) | 1764 (5.3) | 2.80 (2.04-3.84) | .49 |
| Pfizer Bio-NTech | 22 (8.5) | 697 (3.6) | 2.30 (1.53-3.45) | |
Abbreviation: mRNA, messenger RNA.
a
Log binomial model was adjusted for sex, age, race, vaccine manufacturer, and Charlson comorbidity index score.
b
Other category included American Indian, Native Hawaiian, or individuals who identified as belonging to 2 or more race categories.